Available Until 11/11/2022

Expert Discussion: What’s New and Noteworthy in C. difficile?

NOTE: If you attended these as live CE activities AND received CE credit (i.e. a pharmacist CE statement of credit), you are NOT allowed to also receive credit for the home-study on-demand web activity.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities 

Activity Description

Clostridioides difficile infection (CDI) is complex and associated with a significant burden to patients and healthcare resources. A major factor in morbidity and mortality is the propensity for CDI recurrence. After an initial episode, 10-30% of patients develop at least 1 recurrent episode and the risk for recurrence increases with successive recurrences resulting in a substantial burden to patients and the healthcare system. While the use of antibiotics in hospitalized patients has been instrumental in infectious diseases treatments, studies have shown between 30-50% of those prescribed in this setting have been incorrect or ultimately unnecessary.

Challenges for effective management extend to appropriate diagnostic strategies, infection control practices, and therapeutics for treatment and prevention. It is critical that pharmacists and other hospital- and community-based healthcare professionals (HCPs) who may encounter patients with CDI are aware of updates to the CDI treatment guidelines, the data supporting various therapeutic options for CDI, and strategies for reducing CDI recurrence, including patient education and ensuring medication access during transitions of care.

This video roundtable series will increase the knowledge, competence, and performance of pharmacists in applying evidence-based treatment strategies in the treatment and management of patients with CDI. Roundtable #1 will be an Overview of C. difficile Infection Management and Effect on Health Systems1, Roundtable #2 will cover The Next Great Debate: Antimicrobial Management2, Roundtable #3 will discuss Adjunctive Therapy Management for C. difficile: Antibodies and Microbiome3, and Roundtable #4 will Ask the Experts: Management of CDI Q&A4. Learning objectives and accreditation for each video roundtable are detailed below.

Learning Objectives

The target audience for this activity is pharmacists, including those specializing in infectious diseases, gastroenterology, internal medicine, and family medicine, and other healthcare professionals who care for patients with CDI. At the completion of this activity, the participant will be able to:

  • Discuss the guideline-recommended treatment algorithms for Clostridioides difficile infection (CDI).1,4
  • Compare and contrast the data supporting therapeutic options for CDI.2,3,4
  • Determine treatment strategies for reducing CDI recurrence, including patient education, and ensuring medication access during transitions of care.1,4


Christopher M. Bland, Pharm.D., FIDSA, FCCP, BCPS
Clinical Professor
Clinical and Administrative Pharmacy
University of Georgia College of Pharmacy
Infectious Diseases Pharmacist
St. Joseph’s/Candler Health System, Inc.
Savannah, GA

Lindsay Daniels, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Department of Pharmacy, UNC Medical Center
Adjunct Assistant Professor of Clinical Education
University of North Carolina
Chapel Hill, NC

Kevin W. Garey, PharmD, MS, FASHP, FIDSA
Professor and Chair
Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, TX

CE Accreditation

Release Date: November 11, 2021
Expiration Date: November 11, 2022


These activities are jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-21-256-H01-P1, 0221-9999-21-257-H01-P2, 0221-9999-21-258-H01-P3, and 0221-9999-21-259-H01-P4 have been assigned to these home study, knowledge-based activities. Each activity is approved for 0.5 contact hour (0.05 CEU) in states that recognize ACPE providers. The activities are provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Christopher Bland has received fees for non-CME/CE services from Baudax Bio, Merck, and Tetraphase; performed contract research for Merck; received consulting fees from Merck. Lindsay Daniels has no relevant conflicts of interest to report. Kevin Garey has performed contract research for Acurx Pharmaceuticals, Paratek Pharmaceuticals, and Summit Pharmaceuticals.


These activities are supported by educational grants from Ferring Pharmaceuticals and Merck Sharp & Dohme Corp.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.